AngioDynamics (ANGO) ANGO Q1 Financial Results Summary
QuoteReporter
AngioDynamics (ANGO) Q1 2027: Revenue Growth Continues, Loss Narrows — Cautiously Optimistic
AngioDynamics, Inc. (NASDAQ: ANGO) reported its first-quarter financial results for fiscal year 2027, revealing a net sales increase of $5.2 million or +6.9% year-over-year (YoY), reaching $80.9 million compared to $75.7 million in the same quarter last year. This marks the eighth consecutive quarter of double-digit growth in the Med Tech segment, which saw net sales of $39.9 million, up 13.2% from $35.3 million a year ago.
Despite the revenue growth, the company recorded a GAAP net loss of $7.1 million, or a loss per share of $0.17, which is an improvement from a net loss of $10.9 million, or a loss per share of $0.26, in the prior-year quarter. The adjusted loss per share also narrowed to $0.04 from $0.10 a year ago, indicating progress in operational efficiency.
Analyst View
This quarter can be viewed as a cautiously optimistic outcome for shareholders. The revenue growth, particularly in the Med Tech segment, demonstrates AngioDynamics' ability to execute its strategy effectively. The narrowing of losses is a positive sign, suggesting that the company is moving towards profitability, albeit still in the red. The continued focus on Med Tech, especially with products like Auryon and NanoKnife, indicates a solid foundation for future growth.
Key Financial Metrics
- Net Sales: $80.9 million, up $5.2 million or +6.9% YoY
- Med Tech Net Sales: $39.9 million, up $4.6 million or +13.2% YoY
- Med Device Net Sales: $41.0 million, up $0.6 million or +1.4% YoY
- GAAP Gross Margin: 59.4%, up from 55.3% YoY
- GAAP Net Loss: $7.1 million, improved from $10.9 million YoY
- Loss per Share (GAAP): $0.17, improved from $0.26 YoY
- Adjusted Loss per Share: $0.04, improved from $0.10 YoY
- Adjusted EBITDA: $5.0 million, up from $2.2 million YoY
Operational Highlights
- Med Tech Growth: The Med Tech segment continues to be a strong performer, with Auryon achieving $18.9 million in sales, a 14.7% increase YoY. The Mechanical Thrombectomy business also showed resilience, with AlphaVac sales growing 37.4% YoY.
- Gross Margin Improvement: The gross margin increased by 410 basis points YoY, primarily due to favorable pricing and a shift in revenue mix towards Med Tech. However, the company anticipates a lower gross margin in the second half of fiscal 2027.
- Cash Position: As of August 31, 2026, AngioDynamics had $34.0 million in cash and remains debt-free, providing a stable financial footing for future investments.
Strategic Developments
The appointment of Eric Honroth as the new President and CEO, effective November 2, 2026, following Jim Clemmer's retirement, is a significant leadership change. This transition is expected to bring fresh perspectives and strategies to the company, which could further enhance its growth trajectory.
Additionally, the FDA's approval of the Investigational Device Exemption (IDE) for the RELIEF study, evaluating NanoKnife IRE for benign prostatic hyperplasia, opens new avenues for market expansion and product development.
Guidance and Future Outlook
AngioDynamics has reiterated its fiscal year 2027 guidance, projecting net sales between $336.0 million and $341.0 million, with Med Tech net sales growth expected to be between 12% and 15%. The company anticipates adjusted EBITDA in the range of $13.0 million to $16.0 million.
Forward Catalyst
Investors should closely monitor the upcoming quarters for continued execution on growth strategies, particularly in the Med Tech segment. The impact of the new CEO's leadership and the outcomes of the RELIEF study will be critical in shaping AngioDynamics' future performance and market position. Additionally, any updates on gross margin trends and operational efficiencies will be key indicators of the company's path towards profitability.
Here are the extracted tables from the provided press release:
ANGIODYNAMICS, INC. AND SUBSIDIARIES CONSOLIDATED INCOME STATEMENTS (in thousands, except per share data)
Note: All amounts are in thousands.
| Three Months Ended | Aug 31, 2026 | Aug 31, 2025 |
|---|---|---|
| Net sales | $80,915 | $75,711 |
| Cost of sales (exclusive of intangible amortization) | 32,875 | 33,854 |
| Gross margin | 48,040 | 41,857 |
| % of net sales | 59.4% | 55.3% |
| Operating expenses | 55,342 | 52,513 |
| Operating loss | (7,302) | (10,656) |
| Interest expense, net | (88) | (4) |
| Other income (expense), net | 6 | (182) |
| Loss before income tax (benefit) expense | (7,296) | (10,838) |
| Income tax (benefit) expense | (199) | 65 |
| Net loss | (7,097) | (10,903) |
| Loss per share - Basic | (0.17) | (0.26) |
| Loss per share - Diluted | (0.17) | (0.26) |
| Weighted average shares outstanding - Basic | 42,022 | 41,174 |
| Weighted average shares outstanding - Diluted | 42,022 | 41,174 |
ANGIODYNAMICS, INC. AND SUBSIDIARIES CONSOLIDATED BALANCE SHEETS (in thousands)
Note: All amounts are in thousands.
| Aug 31, 2026 | May 31, 2026 | |
|---|---|---|
| Assets | ||
| Current assets: Cash | $33,973 | $53,864 |
| Accounts receivable, net | 44,905 | 48,325 |
| Inventories | 54,953 | 52,436 |
| Prepaid expenses and other | 9,172 | 8,769 |
| Total current assets | 143,003 | 163,394 |
| Property, plant and equipment, net | 27,728 | 27,097 |
| Other assets | 9,308 | 9,463 |
| Intangible assets, net | 61,894 | 67,209 |
| Total assets | $241,933 | $267,163 |
| Liabilities and stockholders’ equity | ||
| Current liabilities: Accounts payable | $26,579 | $31,513 |
| Accrued liabilities | 28,811 | 38,909 |
| Other current liabilities | 4,299 | 4,295 |
| Total current liabilities | 59,689 | 74,717 |
| Deferred income taxes | 4,680 | 5,316 |
| Other long-term liabilities | 13,601 | 16,305 |
| Total liabilities | 77,970 | 96,338 |
| Stockholders’ equity | 163,963 | 170,825 |
| Total Liabilities and Stockholders’ Equity | $241,933 | $267,163 |
Disclaimer
The content on MarketsFN.com is provided for educational and informational purposes only. It does not constitute financial advice, investment recommendations, or trading guidance. All investments carry risk and past performance does not guarantee future results. You are solely responsible for your investment decisions and should conduct independent research and consult a qualified financial advisor before acting. MarketsFN.com and its authors are not liable for any losses or damages arising from the use of this information.
